EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical management of iron deficiency anemia in Japan: iron prescription patterns, treatment effectiveness, and assessments

Miyako Kosugi, Ryo Takezawa, Shun Shiota, Masaru Tsuchikawa, Katsuya Ikuta

International Journal of Hematology · 2024-08 · 120 (2) · 167-178

DOI: 10.1007/s12185-024-03801-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Hematology, online erschienen am 28.05.2024. Verfasst von Miyako Kosugi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Data Science Department, Zeria Pharmaceutical Co., Ltd, 10-11 Nihonbashi Kobuna-Cho, Chuo-Ku, Tokyo, 103-8351, Japan. Hauptthemen laut MEDLINE: Anemia, Iron-Deficiency, Ferric Compounds, Maltose. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ZERIA Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Iron deficiency anemia is one of the most common types of anemia, but real-world clinical management practices in Japan are unclear. This study retrospectively explored iron prescription patterns, treatment effectiveness, and assessments. Patients with at least one treatment period between September 2020 and September 2022 were included and classified into three groups (ferric carboxymaltose [FCM]: 7437 patients, saccharated ferric oxide [SFO]: 98,648 patients, and oral iron: 359,547 patients). Iron-related laboratory values over time and testing proportions were evaluated. Median baseline hemoglobin levels were lowest with FCM (FCM: 8.10 g/dL, SFO: 8.70 g/dL, oral iron: 9.70 g/dL), but changes in hemoglobin levels by 12 weeks were greatest with FCM (FCM: 3.20 g/dL, SFO: 2.60 g/dL, oral iron: 1.70 g/dL). The median serum ferritin level at 8 weeks after FCM treatment was 43.70 ng/mL for ≤500 mg, versus 123.30 ng/mL for >500 to ≤1500 mg. All groups had a low proportion of serum ferritin and transferrin saturation (TSAT) testing at diagnosis (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Iron-DeficiencyFerric CompoundsMaltoseHumansJapanFemaleMaleRetrospective StudiesTreatment OutcomeMiddle AgedAgedIronHemoglobinsAdultFerric Oxide, SaccharatedFerritinsAdministration, OralPractice Patterns, Physicians'

Stichwörter der Autor:innen

Ferric carboxymaltoseIron deficiency anemiaIron replacement therapyJapanReal-world database

Substanzen

Ferric CompoundsMaltoseferric carboxymaltoseIronHemoglobinsFerric Oxide, SaccharatedFerritins

Autor:innen und Institutionen

  • Data Science Department, Zeria Pharmaceutical Co., Ltd, 10-11 Nihonbashi Kobuna-Cho, Chuo-Ku, Tokyo, 103-8351, Japan.
  • Data Science Department, Zeria Pharmaceutical Co., Ltd, 10-11 Nihonbashi Kobuna-Cho, Chuo-Ku, Tokyo, 103-8351, Japan. masaru-tsuchikawa@zeria.co.jp.
  • Program Promotion Department, Hokkaido Blood Center, Sapporo, Japan.

Förderung

  • ZERIA Pharmaceutical

Zitieren

APA

Kosugi, M., Takezawa, R., Shiota, S., Tsuchikawa, M., & Ikuta, K. (2024). Clinical management of iron deficiency anemia in Japan: iron prescription patterns, treatment effectiveness, and assessments. International Journal of Hematology, 120(2), 167-178. https://doi.org/10.1007/s12185-024-03801-4

Vancouver

Kosugi M, Takezawa R, Shiota S, Tsuchikawa M, Ikuta K. Clinical management of iron deficiency anemia in Japan: iron prescription patterns, treatment effectiveness, and assessments. International Journal of Hematology. 2024;120(2):167-178. doi:10.1007/s12185-024-03801-4

BibTeX
@article{Kosugi2024,
  author = {Kosugi, Miyako and Takezawa, Ryo and Shiota, Shun and Tsuchikawa, Masaru and Ikuta, Katsuya},
  title = {Clinical management of iron deficiency anemia in Japan: iron prescription patterns, treatment effectiveness, and assessments},
  journal = {International Journal of Hematology},
  year = {2024},
  volume = {120},
  number = {2},
  pages = {167--178},
  doi = {10.1007/s12185-024-03801-4}
}
Kostenlos starten →